H-CYTE, a medical biosciences company, agreed to acquire SkinDisc, a patent pending tissue regeneration technology provider. Financial terms were not disclosed. "The acquisition of SkinDisc represents another significant addition to our portfolio of potentially life-saving technologies under development. With the rising prevalence of acute, chronic, and surgical wounds over the last decade, and a total addressable market opportunity of $2bn, the H-CYTE team is excited to help foster affordable treatments for those in need of wound care and limb salvaging. To best serve those who can benefit from this proprietary technology, the Company plans to work with surgeons, podiatrists, and physicians to treat patients with severe trauma-based wounds and non-healing chronic wounds," Michael Yurkowsky, H-CYTE CEO.